Recent insights emerging from malignant mesothelioma genome sequencing
- PMID: 25695218
- PMCID: PMC4336947
- DOI: 10.1097/JTO.0000000000000466
Recent insights emerging from malignant mesothelioma genome sequencing
Conflict of interest statement
M. Carbone has pending patent applications on BAP1, and provides consultation for mesothelioma expertise and diagnosis. The remaining authors declare no competing financial interests.
Comment on
-
Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma.Cancer Res. 2015 Jan 15;75(2):264-9. doi: 10.1158/0008-5472.CAN-14-1008. Epub 2014 Dec 8. Cancer Res. 2015. PMID: 25488749
-
Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study.J Thorac Oncol. 2015 Mar;10(3):492-9. doi: 10.1097/JTO.0000000000000436. J Thorac Oncol. 2015. PMID: 25514803
References
-
- Lo Iacono M, Monica V, Righi L, et al. Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study. J Thorac Oncol. 2014 - PubMed
-
- Guo G, Chmielecki J, Goparaju C, et al. Whole exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A and CUL1 in malignant pleural mesothelioma. Cancer Res. 2014 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
